An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation

PharmacoEconomics

Volumn 22, Issue 10, 2004, Pages 621-632

  Keown, Paul A ^a,b,f   Kiberd, Bryce ^c   Balshaw, Robert ^b,d   Khorasheh, Shideh ^b   Marra, Carlo ^a   Belitsky, Philip ^c   Kalo, Zoltan ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Syreon Corporation   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d SIMON FRASER UNIVERSITY   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CANADA; COMORBIDITY; DIALYSIS; ECONOMIC ASPECT; FOLLOW UP; GRAFT REJECTION; HEALTH CARE; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROEMULSION; MONITORING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL;

ADULT; COST-BENEFIT ANALYSIS; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK; TIME FACTORS;

EID: 3242716574     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422100-00001     Document Type: Article

References (41)

1. Canadian Organ Replacement Registry 1998 report, volume 2. Organ donation and transplantation (1981-1996). Ottawa (ON): Canadian Institute for Health Information, 1998
2. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-42
3. Evans RW, Kitzmann DJ. An economic analysis of renal transplantation. Surg Clin North Am 1998; 78: 149-74
4. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7: 659-63
5. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Transplantation 1998; 65: 1450-4
6. Prommool S, Jhangri GS, Cockfield SM, et al. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000; 11: 565-73
7. Humar A, Kerr S, Gillingham KJ, et al. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-3
8. Hall SD, Thummel KE, Watkins PS, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27: 161-5
9. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-18
10. Schroeder TJ, Hariharan S, First MR. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations. Transplant Proc 1995; 27: 837-9
11. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995; 17: 642-54
12. Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals or high-fat meals. Transplantation 1995; 59: 505-11
13. Keown P, Niese D, for the International Sandimmun Neoral Study Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938-44
14. Shaw LM, Holt DW, Keown PA, et al. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 21: 1632-52
15. Mahalati K, Belitsky P, Sketris I, et al. Neoral monitoring by simplified sparse sampling area under the concentration time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62
16. The Canadian Neoral Study Group. Pharmacokinetics of Neoral during the first two weeks following renal transplantation. Transplantation 2001; 72: 1024-32
17. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828-33
18. International Neoral Renal Transplantation Study Group. Neoral absorption profiling and sparse-sample predictors during the first three months after renal transplantation. Am J Transplant 2002; 2: 148-56
19. Barama A, Perner F, Beauregard-Zollinger L, et al. Absorption profiling of Neoral therapy for de novo kidney transplantation: a prospective randomized study comparing sparse sampling to trough monitoring [abstract]. Transplantation 2000, 69 Suppl S162
20. Kahan B, Keown PA, Levy G, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330-50
21. Levy G. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs 2001; 15 (5): 279-90
22. Keown PA, Balshaw R, Krueger H, et al. An economic model of simulect in renal transplantation. Transplantation 2001; 71: 1573-9
23. Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8
24. Chilcott JB, Akehurst RL, Holmes M, et al. The economics of basiliximab (simulect) in preventing acute rejection in renal transplantation. Transplant Int 2002; 15: 486-93
25. Yilmaz S, Barama A, Sepandj S, et al. Relation between hospital length of stay and acute rejection in adult renal transplantation in Canada. Proc Ann Meeting of the Canadian Soc Transplantation 2000 Mar
26. Karim M, Irwin M, Krueger H, et al. Chronic renal dialysis costing model. British Columbia Ministry of Health/Renal Council, 1994 Mar
27. Retail pharmacy dispensed prescription costs: Canada and provinces, 1999, IMS Canada, Inc. [online]. Available from URL: http://www.imshealthcanada.com [Accessed 2001 Feb]
28. Gold MR, Siegal JE, Russell LB, et al. Cost effectiveness in health and medicine. Oxford: Oxford University Press, 1996
29. Whiting J, for the Transplant Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 2000; 70: 1115-21
30. The Canadian Neoral Renal Study Group. A randomized prospective multicenter pharmacoepidemiologic study of neoral (cyclosporine microemulsion) in stable renal graft recipients. Transplantation 1996; 62: 1-10
31. Cole E, Keown P, Landsberg D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients. Transplantation 1998; 65: 505-10
32. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003 Sep 27; 76 (6): 903-8
33. Jacobs P, Bachynsky J, Baladi J-F. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8 (3): 182-9
34. Baladi JF, Menon D, Otten N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 1998; 7: 221-7
35. Andersson F. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? Int J Technol Assess Health Care 1995; 11: 750-61
36. Levy G, Thervet E, Lake J, et al. Patient management by neoral C2 monitoring: an international consensus statement. Transplantation 2002; 73: S12-8
37. 2 monitoring: a review. Transplantation 2002; 73 Suppl. 9: S3-9
38. International Neoral Renal Transplantation Study Group. Randomized international study of Neoral absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157-66
39. Levy GA, Lake JR, Beauregard-Zollinger L, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine blood level monitoring based on two-hour post-dose levels [abstract]. Transplantation 2000; 69: s387
40. Parsons DS, Harris DC. A review of quality of life in chronic renal failure. Pharmacoeconomics 1997; 12 (2 Pt 1): 140-60
41. Painter PL, Luetkemeier MJ, Moore GE, et al. Health-related fitness and quality of life in organ transplant recipients. Transplantation 1997; 64: 1795-800